Preeclampsia and Eclampsia: The Multifaceted Pathophysiology Landscapes

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: closed (1 May 2023) | Viewed by 2968

Special Issue Editor


E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, Biziel University Hospital, Collegium Medicum, Nicolaus Copernicus University, Torun, Poland
Interests: prenatal medicine; Doppler ultrasound; prenatal ultrasound; maternal-fetal pathophysiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pre-eclampsia (PE) and eclampsia are still problematic in perinatology, due to being a direct risk of maternal and neonatal morbidity and mortality, as well as being an iatrogenic cause of prematurity. Even though, PE typically results in hypertensive disorders during the pregnancy, its primal cause is associated with abnormal implantation. Recent studies regarding PE and eclampsia are focused on vascular factors and genetic predisposition to the development of both PE and eclampsia. Some of them have become the basis for selecting patients who are in a group of increased risk of developing PE and eclampsia. 

This Special Issue aims to establish the newest results of research dedicated to both PE and eclampsia on the molecular level. This is of great significance in regard to novel concepts of the pathophysiology of PE and eclampsia. We sincerely encourage everyone interested to submit research papers related to this topic.

Prof. Dr. Mariusz Dubiel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pre-eclampsia
  • eclampsia
  • maternal-fetal pathophysiology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 1487 KiB  
Review
The Role of Peroxisome Proliferator-Activated Receptors in Preeclampsia
by Iason Psilopatis, Kleio Vrettou, Florian Nima Fleckenstein and Stamatios Theocharis
Cells 2023, 12(4), 647; https://doi.org/10.3390/cells12040647 - 17 Feb 2023
Cited by 15 | Viewed by 2391
Abstract
Preeclampsia is a common pregnancy-related hypertensive disorder. Often presenting as preexisting or new-onset hypertension complicated by proteinuria and/or end-organ dysfunction, preeclampsia significantly correlates with maternal and perinatal morbidity and mortality. Peroxisome proliferator-activated receptors (PPARs) are nuclear receptor proteins that regulate gene expression. In [...] Read more.
Preeclampsia is a common pregnancy-related hypertensive disorder. Often presenting as preexisting or new-onset hypertension complicated by proteinuria and/or end-organ dysfunction, preeclampsia significantly correlates with maternal and perinatal morbidity and mortality. Peroxisome proliferator-activated receptors (PPARs) are nuclear receptor proteins that regulate gene expression. In order to investigate the role of PPARs in the pathophysiology of preeclampsia, we conducted a literature review using the MEDLINE and LIVIVO databases. The search terms “peroxisome proliferator-activated receptor”, “PPAR”, and “preeclampsia” were employed and we were able to identify 35 relevant studies published between 2002 and 2022. Different study groups reached contradictory conclusions in terms of PPAR expression in preeclamptic placentae. Interestingly, PPARγ agonists alone, or in combination with well-established pharmaceutical agents, were determined to represent novel, potent anti-preeclamptic treatment alternatives. In conclusion, PPARs seem to play a significant role in preeclampsia. Full article
Show Figures

Figure 1

Back to TopTop